Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemiaArnon P. Kater, Mark‐David Levin, Julia Driessen et al.|Haematologica|2018Cited by 13
Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 studyFatemeh Saberi Hosnijeh, Mark‐David Levin, Lina van der Straten et al.|Experimental Hematology|2020Cited by 8